NCT00259129已完成1 期
Effect of BAY 43-9006 (Sorafenib) on Cardiovascular Safety Parameters in Cancer Patients
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Bayer
- 入组人数
- 53
- 主要终点
- Effect of sorafenib on cardiovascular safety parameters
研究概览
简要总结
This is an open-label, non-randomized Phase I study of sorafenib 400 mg bid (2 x 200 mg tablets) in cancer patients. The primary objective of the study is to evaluate the effect of sorafenib on cardiovascular safety parameters. The secondary objectives are to evaluate the safety, pharmacokinetics, and anti-tumor activity of sorafenib in cancer patients
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with refractory solid cancer for which curative or palliative measures have failed or patients for whom standard treatment is considered ineffective or intolerable
- •Histological or cytological documentation of cancer is required
- •Patients with at least one evaluable lesion. Lesions must be evaluated by Computed Tomography (CT) scan or Magnetic Resonance Imaging (MRI)
- •Life expectancy of at least 12 weeks
- •Left ventricular ejection fraction (LVEF) >=45 % as assessed at the Baseline Multiple Gated Acquisition (MUGA) scan
- •Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to dosing:
- •Hemoglobin > 9.0 g/dL
- •Absolute neutrophil count (ANC) > 1,500/mm3
- •Platelet count >=100,000/dL
- •Total bilirubin <=1.5 times the upper limit of normal
- •Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) <=2.5 x upper limit of normal, except if there is metastatic disease to the liver, in which case <=5 x upper limit of normal is acceptable
- •Prothrombin Time-International Normalized Ratio/Partial Thromboplastin Time (PT-INR/PTT) < 1.5 x upper limit of normal. Patients who are being therapeutically anticoagulated with an agent such as Coumadin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in these parameters exists. For patients on anticoagulation therapy, at least weekly evaluations will be performed until International Normalized Ratio (INR) is stable as defined by the local standard of care
- •Serum creatinine <=1.5 x upper limit of normal
排除标准
- •Colorectal cancer whether refractory or not
- •Supine systolic blood pressure greater than 170 mmHg or diastolic blood pressure greater than 100 mmHg (mean of duplicate readings) at Screening with or without antihypertensives
- •Symptomatic metastatic brain or meningeal tumors
- •Pregnant or breast-feeding patients
研究组 & 干预措施
Arm 1
Experimental
干预措施: Sorafenib (Nexavar, BAY43-9006) (Drug)
结局指标
主要结局
Effect of sorafenib on cardiovascular safety parameters
时间窗: up to 2 months
次要结局
- Adverse Event Collection(after 11 months)
- Anti-tumor activity(after 10 months)
- Pharmacokinetics(after 16 months)
研究者
相似试验
已完成
2 期
Sorafenib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal CancerRecurrent Ovarian CarcinomaPrimary Peritoneal CarcinomaNCT00093626National Cancer Institute (NCI)73
已完成
1 期
BAY 43-9006 (Sorafenib) and Bevacizumab (Avastin) To Treat Solid TumorsNeoplasmsNCT00095459National Cancer Institute (NCI)57
已完成
1 期
Sorafenib and Anastrozole in Treating Postmenopausal Women With Metastatic Breast CancerRecurrent Breast CancerStage IV Breast CancerNCT00217399National Cancer Institute (NCI)35
已完成
2 期
BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung CancerNon-Small-Cell Lung CarcinomaNCT00098254National Cancer Institute (NCI)37
已完成
1 期
Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or GliosarcomaAdult Giant Cell GlioblastomaAdult GlioblastomaAdult GliosarcomaRecurrent Adult Brain TumorNCT00335764National Cancer Institute (NCI)92